Phio Pharmaceuticals (DE:44R3)
FRANKFURT:44R3

Phio Pharmaceuticals Stock Price & Analysis

0 Followers

44R3 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.32 - €2.11
Previous Close€0.33
Volume0.00
Average Volume (3M)2.45K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$14.48M
Total Debt (Recent Filing)$202.00K
Price to Earnings (P/E)N/A
Beta-0.92
Next EarningsMar 30, 2023
EPS Estimate-€0.26
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)N/A
Shares Outstanding13,667,973
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume25
30 Day Avg. Volume2,446
Price to Book (P/B)0.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside1615.30% Upside
Rating ConsensusModerate Buy
AlphaN/A
Number of Analyst Covering1


Financials


44R3 FAQ

What was Phio Pharmaceuticals’s price range in the past 12 months?
Phio Pharmaceuticals lowest stock price was €0.32 and its highest was €2.11 in the past 12 months.
    What is Phio Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Phio Pharmaceuticals’s upcoming earnings report date?
    Phio Pharmaceuticals’s upcoming earnings report date is Mar 30, 2023 which is in 113 days.
      How were Phio Pharmaceuticals’s earnings last quarter?
      Phio Pharmaceuticals released its earnings results on Nov 10, 2022. The company reported -€0.248 earnings per share for the quarter, missing the consensus estimate of €0.344 by -€0.592.
        Is Phio Pharmaceuticals overvalued?
        According to Wall Street analysts Phio Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Phio Pharmaceuticals pay dividends?
          Phio Pharmaceuticals does not currently pay dividends.
          What is Phio Pharmaceuticals’s EPS estimate?
          Phio Pharmaceuticals’s EPS estimate is -€0.26.
            How many shares outstanding does Phio Pharmaceuticals have?
            Currently, no data Available
            What happened to Phio Pharmaceuticals’s price movement after its last earnings report?
            Phio Pharmaceuticals reported an EPS of -€0.248 in its last earnings report, missing expectations of €0.344. Following the earnings report the stock price went down -8.436%.
              Which hedge fund is a major shareholder of Phio Pharmaceuticals?
              Currently, no hedge funds are holding shares in DE:44R3

              ---

              Phio Pharmaceuticals Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -67.82%
              12-Months-Change

              Fundamentals

              Return on Equity
              -62.93%
              Trailing 12-Months
              Asset Growth
              -43.49%
              Trailing 12-Months
              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              Phio Pharmaceuticals

              Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.

              ---

              Forecast EPS vs Actual EPS


              Similar Stocks
              Company
              Price & Change
              Follow
              Fresh Tracks Therapeutics
              Manhattan Scientifics
              Capstone Therapeutics
              Benitec Biopharma
              TransCode Therapeutics

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis